Abstract
Opioids are increasingly used to manage not only acute but also chronic pain and heroine addiction. These patients usually receive many other medications that can interfere with the effects of opioids and vice versa. Patients often need combinations of drugs for their pain management, for treating opioid-related adverse effects or for other indications including depression and anxiety. Several antibiotics can also have interactions with opioids. It is important to understand what potential interactions exist between opioids and other drugs.
Drug interactions can occur due to pharmacokinetic interactions including effects of absorption, metabolic pathways, drug transport through membranes and protein binding. Our knowledge of the metabolism of opioids has significantly increased over the last years and it is now possible to appreciate the role CYP enzymes, mainly CYP 2D6 and 3A4/5, in the metabolism of many commonly used opioids like codeine and oxycodone. Our knowledge regarding the role of the transporter proteins in drug interactions related to opioids is unfortunately meagre. Opioids inhibit the gastrointestinal system and can thus change the absorption of other drugs.
Opioids can have synergistic or additive interactions with other drugs that have analgesic or sedative effects. Endogenous opioids control many physiological functions and exogenous opioids can have effects on all important transmitter systems (cholinergic, GABAergic, dopaminergic and serotonergic). The literature in this field is mainly based on case reports. Interindividual differences play an important role. Other potential interactions include prolongation of the QT-interval and lowering of the threshold for convulsions.
Keywords: Opioid, acetylcholine, dopamine, GABA, serotonin, CYP, transporter protein, QT-interval, drug transport, threshold.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs
Volume: 18 Issue: 37
Author(s): Tarja Heiskanen and Eija Kalso
Affiliation:
Keywords: Opioid, acetylcholine, dopamine, GABA, serotonin, CYP, transporter protein, QT-interval, drug transport, threshold.
Abstract: Opioids are increasingly used to manage not only acute but also chronic pain and heroine addiction. These patients usually receive many other medications that can interfere with the effects of opioids and vice versa. Patients often need combinations of drugs for their pain management, for treating opioid-related adverse effects or for other indications including depression and anxiety. Several antibiotics can also have interactions with opioids. It is important to understand what potential interactions exist between opioids and other drugs.
Drug interactions can occur due to pharmacokinetic interactions including effects of absorption, metabolic pathways, drug transport through membranes and protein binding. Our knowledge of the metabolism of opioids has significantly increased over the last years and it is now possible to appreciate the role CYP enzymes, mainly CYP 2D6 and 3A4/5, in the metabolism of many commonly used opioids like codeine and oxycodone. Our knowledge regarding the role of the transporter proteins in drug interactions related to opioids is unfortunately meagre. Opioids inhibit the gastrointestinal system and can thus change the absorption of other drugs.
Opioids can have synergistic or additive interactions with other drugs that have analgesic or sedative effects. Endogenous opioids control many physiological functions and exogenous opioids can have effects on all important transmitter systems (cholinergic, GABAergic, dopaminergic and serotonergic). The literature in this field is mainly based on case reports. Interindividual differences play an important role. Other potential interactions include prolongation of the QT-interval and lowering of the threshold for convulsions.
Export Options
About this article
Cite this article as:
Heiskanen Tarja and Kalso Eija, Non-Analgesic Effects of Opioids: Interactions Between Opioids and Other Drugs, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582423
DOI https://dx.doi.org/10.2174/138161212803582423 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot topic: Parkinsons Disease (Guest Editor: Jurgen Dinges)]
Current Topics in Medicinal Chemistry Melatonin Redox Activity. Its Potential Clinical Applications in Neurodegenerative Disorders
Current Topics in Medicinal Chemistry Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry Natural Products Combating Neurodegeneration: Parkinson’s Disease
Current Drug Metabolism 5'-Nucleotidases, Nucleosides and their Distribution in the Brain: Pathological and Therapeutic Implications
Current Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design Changing Faces of Transcriptional Regulation Reflected by Zic3
Current Genomics Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Pramipexole Tachyphylaxis and its Management in Bipolar Depression
Letters in Drug Design & Discovery Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines and Structurally Simplified Analogs. Chemistry and SAR Profile as Adenosine Receptor Antagonists
Current Topics in Medicinal Chemistry Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry Left-Right Asymmetry in Embryonic Development and Breast Cancer: Common Molecular Determinants?
Current Medicinal Chemistry Combined Fine-Motor Tests and Self-Assessments for Remote Detection of Motor Fluctuations
Recent Patents on Biomedical Engineering (Discontinued) Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Going up in Smoke? A Review of nAChRs-based Treatment Strategies for Improving Cognition in Schizophrenia
Current Pharmaceutical Design The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders Burden of Bronchiectasis in Indigenous Peoples - How Can it be Improved?
Current Pediatric Reviews Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology Cannabinoids
Current Drug Targets - CNS & Neurological Disorders Advances in Mucomodulator Therapy for Treatment of Excess Airway Mucus in Patients with Asthma, Chronic Obstructive Pulmonary Disease and Cystic Fibrosis
Recent Patents on Materials Science